Compare TACT & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TACT | NEPH |
|---|---|---|
| Founded | 1996 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.2M | 31.0M |
| IPO Year | 1996 | 2004 |
| Metric | TACT | NEPH |
|---|---|---|
| Price | $3.27 | $2.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 57.1K | 46.3K |
| Earning Date | 03-10-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 87.88 | ★ 1000.00 |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | $10.36 | $12.82 |
| Revenue Next Year | N/A | $10.02 |
| P/E Ratio | ★ N/A | $26.91 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $3.06 | $1.51 |
| 52 Week High | $5.70 | $6.42 |
| Indicator | TACT | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.20 | 29.42 |
| Support Level | N/A | N/A |
| Resistance Level | $3.87 | $4.93 |
| Average True Range (ATR) | 0.26 | 0.24 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 31.16 | 5.24 |
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.